TY - JOUR T1 - Prone positioning of patients with moderate hypoxia due to COVID-19: A multicenter pragmatic randomized trial [COVID-PRONE] JF - medRxiv DO - 10.1101/2021.11.05.21264590 SP - 2021.11.05.21264590 AU - M Fralick AU - M Colacci AU - L Munshi AU - K Venus AU - L Fidler AU - H Hussein AU - K Britto AU - R Fowler AU - B Da Costa AU - I Dhalla AU - R Dunbar-Yaffe AU - L Branfield Day AU - T MacMillan AU - J Zipursky AU - T Carpenter AU - T Tang AU - A Cooke AU - R Hensel AU - M Bregger AU - A Gordon AU - E Worndl AU - S Go AU - K Mandelzweig AU - L Castelluci AU - D Tamming AU - F Razak AU - AA Verma AU - COVID Prone Study Investigators Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/11/08/2021.11.05.21264590.abstract N2 - Objectives To assess the effectiveness of prone positioning to reduce the risk of death or respiratory failure in non-critically ill patients hospitalized with COVID-19Design Pragmatic randomized clinical trial of prone positioning of patients hospitalized with COVID-19 across 15 hospitals in Canada and the United States from May 2020 until May 2021.Settings Patients were eligible is they had a laboratory-confirmed or a clinically highly suspected diagnosis of COVID-19, required supplemental oxygen (up to 50% fraction of inspired oxygen [FiO2]), and were able to independently prone with verbal instruction. (NCT04383613).Main Outcome Measures The primary outcome was a composite of in-hospital death, mechanical ventilation, or worsening respiratory failure defined as requiring at least 60% FiO2 for at least 24 hours. Secondary outcomes included the change in the ratio of oxygen saturation to FiO2 (S/F ratio).Results A total of 248 patients were included. The trial was stopped early on the basis of futility for the pre-specified primary outcome. The median time from hospital admission until randomization was 1 day, the median age of patients was 56 years (interquartile range [IQR] 45,65), 36% were female, and 90% of patients were receiving oxygen via nasal prongs at the time of randomization. The median time spent prone in the first 72 hours was 6 hours total (IQR 1.5,12.8) for the prone arm compared to 0 hours (0,2) in the control arm. The risk of the primary outcome was similar between the prone group (18 [14.3%] events) and the standard care group (17 [13.9%] events), odds ratio 0.92 (95% CI 0.44 to 1.92). The change in the S/F ratio after 72 hours was similar for patients randomized to prone compared to standard of care.Conclusion Among hypoxic but not critically patients with COVID-19 in hospital, a multifaceted intervention to increase prone positioning did not improve outcomes. Adherence to prone positioning was poor, despite multiple efforts. Subsequent trials of prone positioning should aim to develop strategies to improve adherence to awake prone positioning.What is already known on this topic Prone positioning is considered standard of care for mechanically ventilated patients who have severe acute respiratory distress syndrome. Recent data suggest prone positioning is beneficial for patients with COVID-19 who are requiring high flow oxygen. It is unknown of prone positioning is beneficial for patients not on high flow oxygen.What this study adds Prone positioning is generally not well tolerated and innovative approaches are needed to improve adherence. Clinical and physiologic outcomes were not improved with prone positioning among hypoxic but not critically ill patients hospitalized with COVID-19.Competing Interest StatementDr. Jonathan Zipursky has received payments for medicolegal opinions regarding the safety and effectiveness of drugs outside the submitted work. Dr. Amol Verma is Provincial Clinical Lead for Quality Improvement in General Internal Medicine at Ontario Health and an AMS Healthcare Fellow in Compassion and Artificial Intelligence. He has received funding for COVID-related research from CIHR, Canadian Frailty Network, St. Michael's Hospital, Sinai Health System, and St. Michael's Hospital Foundation. Dr. Mike Fralick is a consultant for a start-up company that has developed a point of care diagnostic test for COVID-19 using CRISPR. Dr. Fahad Razak has received an award from the Mak Pak Chiu and Mak-Soo Lai Hing Chair in General Internal Medicine, University of Toronto, outside the submitted work and is an employee of Ontario Health.Clinical TrialNCT04383613Funding StatementThis study was funded by St Michaels Hospital Innovation Fund, the Sinai Health Research Fund, and the Sunnybrook Health Sciences Centre Alternate Funding Plan Innovation Fund.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by Clinical Trials Ontario (CTO) ethics committee (reference number 3184), as well as the respective ethics boards of participating centres not governed by CTO (listed below). 1. Beth Israel Deaconess Medical Center (2020P000648) 2. Northwestern Memorial Hospital (STU00212937-CR0001) 3. Sault Area Hospital (2020-12-01) 4. Scarborough Health Network (COV-20-009) I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesPlease reach out to the authors with any requests to access data produced in the present study. ER -